Medicure Engages Knight Therapeutics Inc. to Provide Advisory Services

Apr 14, 2014) - Medicure Inc. ("Medicure" or the "Company") (TSX VENTURE:MPH)(MCUJF), a specialty pharmaceutical company, today announced it has entered into an arrangement with Knight Therapeutics Inc. (TSX VENTURE:GUD), under which Knight will provide advisory services to help advance Medicure's U.S. specialty pharmaceutical business and corporate development initiatives.

"Medicure is pleased to have the opportunity to work with Jonathan Ross Goodman, co-founder of Paladin Labs Inc. and CEO of Knight Therapeutics Inc." stated Dr. Albert D. Friesen, CEO and Chair of Medicure Inc. "We look forward to benefitting from the depth of experience and networks that he has built up in establishing and growing a successful specialty pharmaceutical business."

Published: 14 April 2014
Written by Editor
TSX Venture   Project Updates   Up on News  
Read more: Medicure Inc ( MPH )

http://pennyomega.com/img/lxrx.jpg Lexicon (LXRX) Top-line Results In Type 1 Diabetes Clinical Trial, Crown Equity Holdings Adds Medical Marijuana Site to Its CRWE Network, Bebe Stores (BEBE) Upgraded

Diabetes is a disorder of metabolism—the way the body uses digested food for growth and energy. Most of the food people eat is broken down into glucose, the form of sugar in the blood.

Glucose is vital to your health because it's an important source of energy for the cells that make up your muscles and tissues. It's also your brain's main source of fuel.

The three main types of diabetes are: type 1 diabetes, type 2 diabetes and gestational diabetes.

Published: 14 April 2014
Written by Martin Scareme
Nasdaq   Submitted News  
Read more: Lexicon Pharmaceuticals Inc ( LXRX )

Celladon Receives Breakthrough Therapy Designation From FDA for MYDICAR(R), Novel, First-in-Class Therapy in Development to Treat Heart Failure

MYDICAR is First Gene Therapy Reported to Receive Breakthrough Designation From FDA's Center for Biologics Evaluation and Research (CBER)

April 10, 2014 - Celladon Corporation (CLDN), a clinical-stage biotechnology company developing novel therapies for patients with heart failure and other diseases characterized by SERCA enzyme deficiencies, today announced that its lead product candidate, MYDICAR(R), has been granted breakthrough therapy designation by the U.S. Food and Drug Administration (FDA) for reducing hospitalizations for heart failure in NYHA class III or IV chronic heart failure patients who are NAb negative.

Published: 10 April 2014
Written by Editor
Nasdaq   Industrial   FDA HC Decision   Up on News  
Read more: Celladon Corporation ( CLDN )

Immunovaccine's DepoVax(TM) Technology Underpins New Experimental Therapy for Cervical, Head and Neck Cancers

IMV vaccine adjuvant technology of choice for Dana-Farber's HPV-related cancer clinical trial

Immunovaccine Inc. ("Immunovaccine" or "IMV") (TSX VENTURE:IMV), a clinical stage vaccine company, today announced that its DepoVax™ adjuvanting technology will underlie the design of a new cancer vaccine trial that will be conducted by the Dana-Farber Cancer Institute to treat cervical and head and neck cancer.

In a competitive process, Dana-Farber has been awarded a research grant of $1.2 million for clinical evaluation of its cancer vaccine. The grant from Stand Up To Cancer (SU2C) and the Farrah Fawcett Foundation was awarded to a team of Dana-Farber researchers in a ceremony last evening at the 2014 American Association for Cancer Research (AACR) annual meeting.

Published: 08 April 2014
Written by Editor
TSX Venture   Project Updates   Up on News   Interesting News  
Read more: Immunovaccine Inc ( IMV )

BIND Therapeutics Presents Clinical Data Highlighting Unique Attributes of Lead Cancer Drug Candidate, BIND-014, at AACR 2014 Annual Meeting

Results Demonstrated Increased Dose Intensity of Weekly Dosing vs. Every Three Week Dosing Schedule of BIND-014 and Utility of PSMA as a Biomarker for Patient Selection

BIND Therapeutics, Inc. (BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins™, announced today that clinical data on its lead drug candidate, BIND-014, were presented at the American Association of Cancer Research (AACR) meeting. The clinical data from a completed Phase 1 study demonstrate differentiating attributes of BIND-014 administered with a weekly dosing schedule which may enable increased dose intensity and enhanced therapeutic efficacy of BIND-014. In addition, data supporting the potential utility of PSMA as a target and marker for BIND-014 patient selection were presented.

Published: 08 April 2014
Written by Editor
Nasdaq   Project Updates   Up on News   Interesting News  
Read more: BIND Therapeutics Inc ( BIND )
  1. Peregrine Pharmaceuticals ( PPHM )
  2. Agios Pharmaceuticals ( AGIO )
  3. Questcor Pharmaceuticals ( QCOR )
  4. Response Genetics Inc ( RGDX )
  5. Rexahn Pharmaceuticals ( RNN )